Partial
Partially Aligned
Patient Risk:
Medium
Summary
Partially aligns with the label excerpt regarding adverse-reaction listing in sections 6.1 and 6.2, but overstates causality by implying that postmarketing-listed reactions are necessarily causally associated with the drug.
Category Scores
Accurate Statements
Section 6.1 and 6.2 are adverse-reactions sections (clinical trial adverse experiences and postmarketing experience) for LIPITOR.
Label excerpt headings: '6.1 Clinical Trial Adverse Experiences' and '6.2 Postmarketing Experience'.
The label includes rhabdomyolysis/myopathy and liver enzyme abnormalities as serious adverse reactions discussed in other sections.
Section 6 introductory text: 'Rhabdomyolysis and myopathy [see Warnings and Precautions (5.1)]' and 'Liver enzyme abnormalities [see Warnings and Precautions (5.2)].'
Section 6.2 states that postmarketing reactions are reported voluntarily and that it is not always possible to establish a causal relationship to drug exposure.
Section 6.2 introductory paragraph: 'not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.'
Unsupported Statements
Because 6.1/6.2 lists adverse reactions from clinical trials and postmarketing use, LIPITOR is associated with the adverse reactions described (including rhabdomyolysis/myopathy and liver enzyme abnormalities).
The label supports that adverse reactions are listed/observed/reported, but the postmarketing section explicitly limits causal attribution; the claim’s phrasing implies a causality/association beyond what the label excerpt establishes.
Contradictions
Important Omissions
Clear distinction between 'listed/observed/reported adverse reactions' and 'causally attributable' reactions, especially for postmarketing reports where the label says causality may not be established.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The main issue is causal overstatement regarding postmarketing adverse reactions. The label excerpt itself limits causality in 6.2, so the claim could mislead risk interpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Overstates causality by treating the listing of postmarketing reactions as proof of drug association/causality.
Suggested Improvement
Rephrase to match label language, e.g., 'Sections 6.1 and 6.2 list adverse reactions observed in clinical trials and reported during postmarketing use. In section 6.2, the label notes that a causal relationship to drug exposure may not be established for voluntary reports.'